谷歌浏览器插件
订阅小程序
在清言上使用
VIPCreated with Sketch.

Maintenance Durvalumab after First-Line Chemotherapy in Patients with HER2-negative Advanced Oesophago-Gastric Adenocarcinoma: Results from the Randomised PLATFORM Study

C. Fong, B. Patel,C. Peckitt, E. Bourmpaki,L. Satchwell, S. Cromarty, S. Kidd,K. von Loga,M. Uhlik,R. Begum, T. Rana,T. Waddell,S. Darby, A. Bradshaw,T. Roques, C. Morgan, C. Rees,R. Herbertson,P. Das, C. Thompson,M. Hewish,R. Petty,F. Thistlethwaite,S. Rao,N. Starling,I. Chau,D. Cunningham

ESMO Open（2024）

引用 0|浏览2
关键词
durvalumab,checkpoint inhibitor,oesophageal adenocarcinoma,gastric cancer,maintenance therapy
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要